Jordi Rodon Ahnert, MD
Medical Oncology · Houston, TXNPI 1841733102
Payments from drug & device makers
Across 1,649 payments — averaging $17,062 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9M
- Deciphera Pharmaceuticals Inc.$4.5M
- Aadi Bioscience, Inc.$3.2M
- Pfizer$1.7M
- Amgen$1.4M
- Taiho Oncology, Inc.$1.2M
- plus $7.2M from 22 others
Across 10 payments — averaging $1153.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- Pfizer$4K
- Amgen$2K
- Servier Pharmaceuticals LLC$296
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $9,011,137 |
| Deciphera Pharmaceuticals Inc. | 935 | $4,526,628 |
| Aadi Bioscience, Inc. | 17 | $3,166,285 |
| Pfizer | 95 | $1,675,874 |
| Amgen | 11 | $1,405,602 |
| Taiho Oncology, Inc. | 59 | $1,169,883 |
| Novartis | 20 | $1,117,160 |
| Eli Lilly | 6 | $913,792 |
| Incyte Corporation | 279 | $857,224 |
| Mirati Therapeutics, Inc. | 13 | $632,151 |
| GSK | 63 | $617,073 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $532,468 |
| Blueprint Medicines Corporation | 2 | $487,595 |
| Genentech, Inc. | 18 | $413,710 |
| E.r. Squibb & Sons, L.L.C. | 22 | $283,108 |
| AstraZeneca | 3 | $268,652 |
| Beone Medicines USA, Inc. | 13 | $212,828 |
| Alnylam Pharmaceuticals Inc. | 7 | $211,637 |
| Sanofi US Services Inc. | 1 | $195,038 |
| Ipsen Pharma SAS | 5 | $175,963 |
| Bayer | 15 | $118,139 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | $117,937 |
| Partner Therapeutics, Inc. | 1 | $16,566 |
| Janssen Global Services, LLC | 4 | $8,045 |
| Merck Kgaa | 7 | $599 |
| Macrogenics, Inc. | 1 | $550 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Genentech USA, Inc. | 1 | $46 |
How this compares
$28,135,737 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Sarina Piha PaulHouston$26M
- Jenny ChangHouston$17.8M
- Hun LeeHouston$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.